Home › Type 2 Diabetes › NCT07465224

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus

Who can join

Ages 18 to 65 · All sexes

Inclusion Criteria:

* Is an adult patient with a confirmed diagnosis of T2DM
* Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
* Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
* Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)

Exclusion Criteria:

* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods

Note: other protocol defined inclusion/exclusion criteria apply

About the study

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

What is being tested

• ALN-4324 (drug)
• Placebo (drug)

Sponsor: Alnylam Pharmaceuticals · Participants: 24 · Started: Jan 15, 2026

Contact the study team

• Alnylam Clinical Trial Information Line · Phone: 1-877-ALNYLAM
• Alnylam Clinical Trial Information Line · Phone: 1-877-256-9526

Official record on ClinicalTrials.gov — NCT07465224

Locations in the U.S.

Conditions

• Type 2 Diabetes

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.